KalVista Pharmaceuticals (KALV) Free Cash Flow Growth (1y) (2015 - 2025)
KalVista Pharmaceuticals (KALV) Free Cash Flow Growth (1y) (2015 - 2025) Analysis & Trends
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | FCF Growth (1y) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 66,621.14 Bn | 66,620.85 Bn | - | 7.12% |
| 2 | Nanobiotix | 1,915.18 Bn | 1,915.11 Bn | - | - |
| 3 | Akari Therapeutics | 1,014.18 Bn | 1,014.18 Bn | - | - |
| 4 | BeOne Medicines | 471.27 Bn | 466.48 Bn | 1.35 Bn | 1,092.51% |
| 5 | Vertex Pharmaceuticals | 121.81 Bn | 114.57 Bn | 2.59 Bn | 66.37% |
| 6 | Regeneron Pharmaceuticals | 69.58 Bn | 60.82 Bn | 3.31 Bn | 3.98% |
| 7 | Belite Bio | 62.72 Bn | 62.72 Bn | - | - |
| 8 | Argenx Se | 55.51 Bn | 50.33 Bn | 1.41 Bn | - |
| 9 | Revolution Medicines | 37.35 Bn | 37.35 Bn | - | - |
| 10 | KalVista Pharmaceuticals | 1.36 Bn | 1.36 Bn | 49.41 Mn | -36.01% |
Historic Data
Download Data| Date | Value |
|---|---|
| Jul 31, 2025 | -36.01% |
| Apr 30, 2025 | -172.92% |
| Oct 31, 2024 | -100.27% |
| Jul 31, 2024 | -50.67% |
| Apr 30, 2024 | 34.58% |
| Jan 31, 2024 | -199.41% |
| Oct 31, 2023 | 4.61% |
| Jul 31, 2023 | -12.99% |
| Apr 30, 2023 | 15.52% |
| Jan 31, 2023 | 34.79% |
| Oct 31, 2022 | -4.45% |
| Jul 31, 2022 | -31.30% |
| Apr 30, 2022 | -142.60% |
| Jan 31, 2022 | -87.72% |
| Oct 31, 2021 | -149.86% |
| Jul 31, 2021 | -399.22% |
| Apr 30, 2021 | 12.26% |
| Jan 31, 2021 | 42.02% |
| Oct 31, 2020 | -0.47% |
| Jul 31, 2020 | 68.26% |